Panel Discussion: Strategic Funding & Resource Allocation in ALS Research: Overcoming Barriers to Clinical Development
Time: 8:30 am
day: Conference Day One
Details:
- ALS trials are highly resource-intensive, with significant financial and logistical demands, creating a major barrier for therapies entering development
- Strategies like synthetic control arms, remote visits, and digital biomarkers can cut costs and reduce patient burden, though validation of these technologies remains a challenge
- Investors prioritize ALS programs with unique therapeutic approaches, including gene therapy and alternatives to heavily funded pathways like TDP-43, focusing on clinical differentiation and scalability
- Partnerships between startups, big pharma, and venture funds are key to addressing validation gaps and improving the efficiency of ALS clinical trial execution while prioritizing patient needs
